In Jan. 2025, TNM001 Phase III Clinical Trial (TNM001-301) achieved enrollment of 1,500 participants.
In Feb. 2025, World's first rcombinant anti-tetanus monoclonal antibody named Sintetol® officially approved for marketing in China by NMPA.
In Mar. 2025, Trinomab completed the series C financing.
In Apr. 2025, Sintetol® was Included in Macao SAR's Catalog of "New Drugs Conditionally Approved for Use by Local Medical Institutions and Application for Registration and Market Launch".
In Jun. 2025, Phase III clinical trial results of Siltartoxatug Injection (Brand Name: Sintetol®) were accepted to publish in the top international journal "Nature Medicine" (Impact Factor IF=50.0).
In Sep. 2024, Trinomab successfully obtained the dual certification of ISO14001 and ISO45001 for its manufacturing qualifications.
In Oct. 2024, Trinomab completed its B+round financing.
In Oct.2024, : TNM002 clinical results were presented orally at the US/European Emergency Medicine Conferences.
In Nov. 2024, TNM001, an anti-RSV mAb (Respiratory Syncytial Virus) was approved and entered Phase III clinical trial in China.
In Jun. 2023, Trinomab completed its share reform and renamed the company as Zhuhai Trinomab Biopharmaceutical Co., Ltd.
In Dec.2023, TNM002, the world first-in-class anti-tetanus monoclonal antibody was accepted and included in the priority review process for NDA approval by NMPA.
In Mar. 2022, TNM002 obtained the title of breakthrough drug by CDE of NMPA.
In Nov. 2022, Trinomab lauched TNM002 Phase III clinical trial.
In Nov. 2022, Trinomab completed approximately RMB 750 million in Series B financing.
In Apr. 2021, Trinomab GMP manufacturing facilities at Zhuhai International Health Park were established for mAb production operation. At the same time, Trinomab completed Round A Financing of nearly RMB 450 million.
In Aug. 2021, Trinomab completed Round A+ Financing of RMB 700 million.
In Nov. 2020, The world's first fully human anti-tetanus monoclonal antibody (TNM002) was approved for Phase-I clinical trial (by FDA and NMPA). TNM002 is one of proprietary products and developed exclusively by Trinomab.
In Apr. 2019, Trinomab established the longterm strategic collaboration agreement with WuXi Biologics.
In Nov. 2019, Trinomab signed up a regional license-out agreement with Changchun BCHT Bio of developing the fully human monoclonal antibody against tetanus toxin.
In Sept.2018, Trinomab completed Pre-A round financing of RMB 200 million.
In May. 2017, Trinomab new drug discovery center was inoculated for the development of fully human monoclonal antibodies.
In Sep. 2016, Trinomab was elected and named by Zhuhai Gorvement as an Innovation and Entrepreurship Institution.
In Dec.17th 2015, Trinomab Biotech Co., Ltd was officially incorporated.
In Jan. 2025, TNM001 Phase III Clinical Trial (TNM001-301) achieved enrollment of 1,500 participants.
In Feb. 2025, World's first rcombinant anti-tetanus monoclonal antibody named Sintetol® officially approved for marketing in China by NMPA.
In Mar. 2025, Trinomab completed the series C financing.
In Apr. 2025, Sintetol® was Included in Macao SAR's Catalog of "New Drugs Conditionally Approved for Use by Local Medical Institutions and Application for Registration and Market Launch".
In Jun. 2025, Phase III clinical trial results of Siltartoxatug Injection (Brand Name: Sintetol®) were accepted to publish in the top international journal "Nature Medicine" (Impact Factor IF=50.0).
In Sep. 2024, Trinomab successfully obtained the dual certification of ISO14001 and ISO45001 for its manufacturing qualifications.
In Oct. 2024, Trinomab completed its B+round financing.
In Oct.2024, : TNM002 clinical results were presented orally at the US/European Emergency Medicine Conferences.
In Nov. 2024, TNM001, an anti-RSV mAb (Respiratory Syncytial Virus) was approved and entered Phase III clinical trial in China.
In Jun. 2023, Trinomab completed its share reform and renamed the company as Zhuhai Trinomab Biopharmaceutical Co., Ltd.
In Dec.2023, TNM002, the world first-in-class anti-tetanus monoclonal antibody was accepted and included in the priority review process for NDA approval by NMPA.
In Mar. 2022, TNM002 obtained the title of breakthrough drug by CDE of NMPA.
In Nov. 2022, Trinomab lauched TNM002 Phase III clinical trial.
In Nov. 2022, Trinomab completed approximately RMB 750 million in Series B financing.
In Apr. 2021, Trinomab GMP manufacturing facilities at Zhuhai International Health Park were established for mAb production operation. At the same time, Trinomab completed Round A Financing of nearly RMB 450 million.
In Aug. 2021, Trinomab completed Round A+ Financing of RMB 700 million.
In Nov. 2020, The world's first fully human anti-tetanus monoclonal antibody (TNM002) was approved for Phase-I clinical trial (by FDA and NMPA). TNM002 is one of proprietary products and developed exclusively by Trinomab.
In Apr. 2019, Trinomab established the longterm strategic collaboration agreement with WuXi Biologics.
In Nov. 2019, Trinomab signed up a regional license-out agreement with Changchun BCHT Bio of developing the fully human monoclonal antibody against tetanus toxin.
In Sept.2018, Trinomab completed Pre-A round financing of RMB 200 million.
In May. 2017, Trinomab new drug discovery center was inoculated for the development of fully human monoclonal antibodies.
In Sep. 2016, Trinomab was elected and named by Zhuhai Gorvement as an Innovation and Entrepreurship Institution.
In Dec.17th 2015, Trinomab Biotech Co., Ltd was officially incorporated.
